Train Babcock Advisors’s VanEck Biotech ETF BBH Stock Holding History

Train Babcock Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$902K	Buy	+7,237	New	+$924K	0.4%	54
2017 Q3	–	Sell	-6,227	Closed	-$782K	–	87
2017 Q2	$782K	Sell	6,227 -3,165	-34%	-$382K	0.34%	60
2017 Q1	$1.12M	Buy	9,392 +1,090	+13%	+$127K	0.5%	50
2016 Q4	$893K	Buy	8,302 +5,567	+204%	+$605K	0.37%	62
2016 Q3	$315K	Buy	+2,735	New	+$312K	0.13%	96

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.11B AUM 13.1% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Train Babcock Advisors's BBH Position: Q4 2017 in Review

Train Babcock Advisors opened a new position in VanEck Biotech ETF (BBH) in Q4 2017: 7,237 shares worth $902K. The stake represents 0.4% of the portfolio and ranks #54 among its holdings. This is a return to the name: Train Babcock Advisors previously reported a position in BBH as recently as Q2 2017.

Train Babcock Advisors first reported a position in BBH in Q3 2016 and has held it in 5 quarters since. The position peaked at $1.12M in Q1 2017. 82 funds tracked by Wall St. Rank hold BBH as of Q4 2017.

Train Babcock Advisors held 7,237 shares of VanEck Biotech ETF worth $902K as of Q4 2017.
VanEck Biotech ETF was a new Train Babcock Advisors position in Q4 2017.
VanEck Biotech ETF made up 0.4% of Train Babcock Advisors's portfolio in Q4 2017, its #54 holding.
Train Babcock Advisors first reported a position in VanEck Biotech ETF in Q3 2016 and has held it in 5 quarters since.
Train Babcock Advisors's VanEck Biotech ETF position peaked at $1.12M in Q1 2017.
82 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2017.

Based on Train Babcock Advisors's 13F filing for Q4 2017, filed 10 Jan 2018.